GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

Rating:
Buy ANDS
up 56.77 %

Anadys Pharmaceuticals, Inc. (ANDS) rated Buy with price target $5 by Roth Capital

Posted on: Friday,  Feb 19, 2010  9:25 AM ET by Roth Capital

Roth Capital rated Buy Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on 02/19/2010, when the stock price was $2.36. Since
then, Anadys Pharmaceuticals, Inc. has gained 56.78% as of 11/23/2011's recent price of $3.70.
If you would have followed this Roth Capital's recommendation on ANDS, you would have gained 56.77% of your investment in 642 days.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/19/2010 9:25 AM Buy
None
2.36 5.00
as of 12/31/2010
1 Week up  4.06 %
1 Month up  19.62 %
3 Months down  -44.82 %
1 YTD down  -45.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy